
MD | Assistant Professor at HMS | MGH Bone Marrow Transplantation and Cellular Therapy | Leick Lab | @OslerHousestaff 2014-2017
Boston, MA
Joined December 2016
- Tweets26
- Following121
- Followers254
- Likes163
Mark Leick retweeted
Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators @MGHNeurosurg and @MGHCancerCenter!
nej.md/3VnjUIq
Mark Leick retweeted
Excited to share that @Majzner_Lab is moving to @DanaFarber @DFBC_PedCare as of Sept. Bittersweet to leave Stanford, but looking forward to growing our research program both in the lab and in the clinic. Hiring postdocs, scientists & lab manager- please reach out if interested!
Mark Leick retweeted
🚨Next-level T cell engineering enters the clinic! DNA base editor to simultaneously silence CD7 (minimize fratricide), TCRB (minimize GVHD), and CD52 (host pre-conditioning) in allo CD7 CAR-expressing T cells for T-ALL. No DNA cuts, no translocations.
nejm.org/doi/full/10.1056/NE…
Mark Leick retweeted
Really happy to see the wonderful work from colleagues in Rome using 3rd gen GD2 CARs for neuroblastoma. This is the largest series of CAR T responses in a solid tumor to date & the fact that it’s in a pediatric cancer is awesome! Bravo! nejm.org/doi/full/10.1056/NE…
CAR-T coming for a non-malignant indication near you
thelancet.com/journals/lance….
Mark Leick retweeted
Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy. rdcu.be/c7avS
Mark Leick retweeted
'Multiomics STEP up in correlative analysis of response to CAR T cells'. In this article, Mark Leick & Marcela Maus discuss the potential of cfDNA-based analyses to inform on CAR T cell expansion kinetics & tumour-infiltration patterns in patients: nature.com/articles/s41571-0…
Mark Leick retweeted
We are hiring! Interested in engineering, genomics and T cell therapies for cancer? Want to work with awesome people? Looking for a great place to live? Come join us in St Louis!
More info about us here: sites.wustl.edu/nathansinghl…
Apply here: wustl.wd1.myworkdayjobs.com/…
Please RT!
Mark Leick retweeted
Great talk on germline HLH variants affecting CAR-T toxicity by @Mark_Leick @MarcelaMaus , looking forward to collaborating! #ASH22 @DrFredLocke
Mark Leick retweeted
If you assumed we are talking about CAR-T, you would be correct! @jaepark @MarcelaMaus @Mark_Leick #ASH22
Mark Leick retweeted
Thoughtful piece in @NatureMedicine from @Eddie_Cliff, Reid Merryman, Philippe Armand and Caron Jacobson @harvardmed @DanaFarber on #CARTcells in #DLBCL. Thanks for writing this! #lymphoma #lymsm
Our commentary in @NatureMedicine addresses 3 critical unanswered questions in the use of 2L CAR-T for DLBCL: 1) How to approach patients w chemo-sensitive disease? 2) Bridging therapy & 3) cost. Would love to hear your thoughts (no paywall): rdcu.be/cZfkl #lymsm
Mark Leick retweeted
We're excited to share the 1st clinical experience delivering intracranial B7-H3 #CARTcells to treat #DIPG in @CD_AACR, a journal of the @AACR. #1: on behalf of @seattlechildren & @SCTherapeutics, we are humbled by our patients' trust and bravery. (1/2)
aacrjournals.org/cancerdisco…
Mark Leick retweeted
SPOTLIGHT: Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell #lymphoma @Mark_Leick @SatyenGohil @gaddyg @MarcelaMaus. Originally published in @NatureMedicine. To read our summary click ow.ly/zu6N50KVJTZ and scroll all the way down.
Mark Leick retweeted
Large propensity score matched study
#axicel vs #tisacel in @NatureMedicine by @BachyEmmanuel et al
Closely matched large cohorts
⬆️ ORR, CR, PFS & OS advantage for #axicel pts
1 yr OS 63.5% vs 48.8% p=0.0072
⬆️ G1-2 CRS, & all grade ICANS in #axicel pts
#CART #lymsm #DLBCL
Unbelievably exciting to see the benefits of CAR-T being extended safely for non malignant conditions with high morbidity statnews.com/2022/09/15/lupu…
Its finally out @NatureMedicine ! Excited to share our work identifying an association between CAR-Tregs and relapse/resistance after CAR-T cell treatment in DLBCL via scRNAseq and then modeling it in vivo (along with much more!)
[1/6 🧵] Today @NatureMedicine! Cellular dynamics monitored over time at the #SingleCell level reveals new insights into why some patients with large B cell lymphomas respond better than others to #CARTcell therapy rdcu.be/cVqVs
Read the main takeaways below 👇!
Thrilled to kick off the 10th Annual Industrial Symposium in Montpellier with the keynote lecture this morning!
Incredibly honored to be recognized and supported by the Damon Runyon Cancer Research and Mark Foundations and to be blessed with such a wonderful mentor @MarcelaMaus @MGHCancerCenter
Replying to @DamonRunyon
@Mark_Leick, the @TheMarkFdn Physician-Scientist, will use genetic modifications and/or a dual targeting approach to improve CAR T cell therapy for acute myeloid leukemia.
























